| Gastric Adenocarcinoma

Enhertu vs Trazimera

Side-by-side clinical, coverage, and cost comparison for gastric adenocarcinoma.

Deep comparison between: Enhertu vs Trazimera with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTrazimera has a higher rate of injection site reactions vs Enhertu based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Trazimera but not Enhertu, including UnitedHealthcare

Category

Enhertu

Trazimera

At A Glance

RouteIV infusion

FrequencyEvery 3 weeks

ClassHER2-directed antibody-drug conjugate with topoisomerase I inhibitor

RouteIV infusion

FrequencyWeekly or every 3 weeks

ClassHER2/neu receptor antagonist

Indications

Breast Carcinoma
Non-Small Cell Lung Carcinoma
Gastric Adenocarcinoma

Breast Carcinoma
Gastric Adenocarcinoma
Adenocarcinoma of the gastroesophageal junction

Dosing

Breast Carcinoma (HER2-positive, HER2-low, or HER2-ultralow) 5.4 mg/kg IV infusion every 3 weeks until disease progression or unacceptable toxicity

Breast Carcinoma (HER2-positive, first-line with pertuzumab) Cycle 1 Day 1: 5.4 mg/kg IV followed by pertuzumab 840 mg; subsequent cycles: 5.4 mg/kg IV followed by pertuzumab 420 mg every 3 weeks

Non-Small Cell Lung Carcinoma (HER2-mutant) 5.4 mg/kg IV infusion every 3 weeks until disease progression or unacceptable toxicity

Gastric Adenocarcinoma (HER2-positive) 6.4 mg/kg IV infusion every 3 weeks until disease progression or unacceptable toxicity

Breast Carcinoma (adjuvant) 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly for 12-18 weeks, then 6 mg/kg IV q3w to complete 52 weeks total; alternatively, 8 mg/kg loading dose over 90 min IV, then 6 mg/kg IV q3w for 52 weeks.

Breast Carcinoma (metastatic) 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly IV until disease progression.

Gastric Adenocarcinoma, Adenocarcinoma of the gastroesophageal junction 8 mg/kg loading dose over 90 min IV, then 6 mg/kg IV over 30-90 min q3w until disease progression.

Contraindications

—

Drug Interactions

189View drug interactions

1058View drug interactions

Adverse Reactions

Most common (>=20%) Decreased white blood cell count, nausea, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, fatigue, decreased platelet count, increased aspartate aminotransferase, increased alanine aminotransferase, increased blood alkaline phosphatase, vomiting, alopecia, decreased blood potassium, constipation, musculoskeletal pain, diarrhea, decreased appetite

Serious Interstitial lung disease, pneumonitis, pneumonia, febrile neutropenia, vomiting, nausea, hypokalemia, pulmonary embolism, sepsis

Most common Fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, myalgia

Serious Cardiomyopathy, severe infusion reactions, pulmonary toxicity, embryo-fetal toxicity, exacerbation of chemotherapy-induced neutropenia

Postmarketing Infusion reaction, oligohydramnios or oligohydramnios sequence, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome

Pharmacology

Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate consisting of a humanized anti-HER2 IgG1 antibody linked to a topoisomerase I inhibitor (DXd). After binding to HER2 on tumor cells, the drug undergoes internalization and lysosomal cleavage, releasing the membrane-permeable DXd that causes DNA damage and apoptotic cell death.

Trastuzumab-qyyp is a HER2/neu receptor antagonist that inhibits proliferation of HER2-overexpressing human tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) preferentially on HER2-overexpressing cancer cells compared with cells that do not overexpress HER2.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Enhertu